What is AISAP's primary focus?

AISAP specializes in Point-of-Care Assisted Diagnosis, supporting clinicians with real-time acquisition guidance, immediate interpretation, and multi-organ diagnoses using point-of-care ultrasound.

When was AISAP founded?

AISAP was founded in January 2022.

What is the name of AISAP's core product?

AISAP's core product is POCAD, an AI-powered, secure cloud-based platform for ultrasound diagnosis.

What is AISAP's total funding to date?

AISAP has raised a total of $13,000,000.

When was AISAP's most recent funding round, and who were the lead investors?

AISAP's most recent funding round occurred in May 2024, with Shoni Health Ventures and Harel Insurance & Finance as lead investors.

How many employees does AISAP currently have?

AISAP has an employee count in the 11-50 range.

Who are the co-founders of AISAP?

The co-founders of AISAP are Adiel Am-Shalom, Ehud Raanani, and Robert Klempfner.

In which country is AISAP headquartered?

AISAP is headquartered in Ramat Gan, Israel.

AISAP

Point-of-Care Assisted Diagnosis

Health Tech & Life Sciences

Active

Seed Ramat Gan, Israel Founded 2022

Website ↗ LinkedIn

Last updated 2026-06-18

Raised $13M funding round led by Shoni Health Ventures, May 2024
Raised funding round led by Harel Insurance & Finance, Feb 2022

Total raised

$13.0M

Last: 2024-05

Stage

Seed

Founded

2022

Headcount

Ramat Gan, Israel

Sector

Health Tech & Life Sciences

About

AISAP supports clinicians using point-of-care ultrasound with real-time acquisition guidance, immediate interpretation, and multi-organ diagnoses, leading to exceptional clinical outcomes and health care efficiency.

AISAP developed POCAD, an intuitive, easy-to-use, secure cloud-based platform that provides AI-powered ultrasound diagnosis anywhere and at any time, designed to empower clinicians and connect care teams to provide immediate, efficient, and fast treatment, right at the patient's bedside.

POCAD is a deep-learning, secure, cloud-based platform that provides real-time analysis of images and data from any ultrasound device, assesses the patient’s condition, and predicts patient outcomes.

AISAP’s CARDIO AI-powered Point-of-Care Ultrasound Diagnostic Software received FDA clearance.

Funding history · 2 rounds · $13.0M total

2024-05

$13.0M

★ Shoni Health Ventures ★ Harel Insurance & Finance

2022-02

Undisclosed

★ Harel Insurance & Finance Shoni Health Ventures

Q&A

What is AISAP's primary focus?: AISAP specializes in Point-of-Care Assisted Diagnosis, supporting clinicians with real-time acquisition guidance, immediate interpretation, and multi-organ diagnoses using point-of-care ultrasound.
When was AISAP founded?: AISAP was founded in January 2022.
What is the name of AISAP's core product?: AISAP's core product is POCAD, an AI-powered, secure cloud-based platform for ultrasound diagnosis.
Has AISAP received any regulatory clearances for its products?: Yes, AISAP’s CARDIO AI-powered Point-of-Care Ultrasound Diagnostic Software has received FDA clearance.
What is AISAP's total funding to date?: AISAP has raised a total of $13,000,000.
When was AISAP's most recent funding round, and who were the lead investors?: AISAP's most recent funding round occurred in May 2024, with Shoni Health Ventures and Harel Insurance & Finance as lead investors.
How many employees does AISAP currently have?: AISAP has an employee count in the 11-50 range.
Who are the co-founders of AISAP?: The co-founders of AISAP are Adiel Am-Shalom, Ehud Raanani, and Robert Klempfner.
In which country is AISAP headquartered?: AISAP is headquartered in Ramat Gan, Israel.